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The neuropeptide substance P and the polyamine compound 48jS0, both known to activate mast cell secretory processes, increased the rate of 
GTP,S binding to G-proteins purified from calf brain (G,/Gi mixture). The GTPase activity of G-proteins was also increased by substance P and 
compound 4Sj80 in a dose-dependent and Mg2+-dependent way. These effects were similar to those of the wasp venom peptide mastoparan, another 
histamine releaser of rat peritoneal and human skin mast cells. This suggests that the secretory property of compound 48/80 and substance P is 
not due to a receptor-mediated process but, like mastoparan, results from a direct activation of G-proteins. 
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1. INTRODUCTION 
Mastoparan, a peptide toxin from wasp venom, has 
recently been proposed to mimic receptors by activating 
GTP-binding regulatory proteins (G-proteins) [ 11. 
Mastoparan is a potent histamine releaser from rat peri- 
toneal mast cells [Z]. At the cellular level, mastop~an 
shares common properties with compound 48/80 and 
also with substance P [3]. These similarities include (i) 
the kinetics of release and the ionic requirements for 
mast cell reactivity; (ii) the desensitization of mast cells 
to these stimuli, following the hydrolysis of sialic acid 
residues of the cell surface; (iii) the inhibitory effect of 
pertussis toxin; and (iv) the involvement of phospho- 
lipase C activation [3]. Thus, we have proposed a com- 
mon mechanism for action for these three stimuli of 
mast cells, related to a common target which might be 
either a receptor or a G-protein 131. However, no 
evidence for selective membrane receptors of these 
stimuli has been obtained. Effective concentrations of 
substance P to trigger mast cells (PM) are well above 
those required to stimulate neurokinin receptors (nM) 
and the existence of such receptors on mast cells has 
been extensively questioned (4-61. In contrast, the role 
of G-proteins in mast cell exocytosis has been larely 
documented [3,7-l 11. The data presented here show 
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that compound 48180 and substance P increased both 
the rate of nucleotide binding and GTPase activity of 
purified G-proteins. 
2. MATERIALS AND METHODS 
Pu~f~cation of a mixed preparation of Go and Gr was obtained 
from calf brain membranes by successive elution from DEAE 
Sephacel (Pharmacia), AcA 34 (LKB) and heptylamine-Sepharose 
columns as described by Sternweis and Robishaw [12]. This prepara- 
tion mostly contains G, [13,14]. All incubations were carried out in 
buffer A (50 mM Na-Hepes, pH 8, 1 mM EDTA, 1 mM dithio- 
threitol) containing the concentration of nucleotides and Mg*+ in- 
dicated in the figure legends. G-proteins were r~onstituted into phos- 
pholipid vesicles, according to the method of Sternweis [is]. G- 
proteins (about 120 pmol) in 500 ~1 of buffer A plus 0.02% Lubrol 
12A9 were mixed with 100 ~1 of buffer A plus 0.84% sodium cholate, 
0.05% dioleoyl-phosphatidylcholine, 0.05% bovine brain phos- 
phatidylethanolamine and 0.067% bovine brain phosphatidylserine. 
The suspension was held at 0°C overnight. The assay of [?S]GTPyS 
(NEN-Du Pont, Boston, MA) binding was performed according to 
Ferguson et at. [ 161, except hat 0.1% bovine serum albumin was add- 
ed to reduce the non-specific binding observed with the higher concen- 
trations of substance P. GTPase activity was determined according to 
Brandt et al. [17] and Higashijima et al. [18] with [r-“P]GTP (Amer- 
sham, England). Lipids, mastoparan and compound 48/80 were pur- 
chased from Sigma (St. Louis, MO), substance P, neurokinin A and 
neurokinin B from Bachem Feinchemikaljen AG (Bubendorf, 
S~tzerIand). 
3. RESULTS AND DISCUSSION 
The effect of the neuropeptide substance P and com- 
pound 48/80 on the rate of GTPyS binding was tested 
using a preparation of G,/G, proteins (in which G, was 
characterized as the major holoprotein [13,14]). As 
shown in fig. 1, 500 PM of substance P and 100 pg/ml 
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Fig.1. Substance P and compound 48180 increased the rate of [‘%I- 
GTPyS binding. [35S]GTPyS binding was assayed at 25’C using G- 
proteins that had been reconstituted into phospholipid vesicles as de- 
scribed under section 2. The assay medium was buffer A that contain- 
ed 1 mM Mg’+ and 0.1 CM [“S]GTPyS either with 500 FM substance 
P (e) or iOO~g/ml of compound 48180 (A) or with no substances 
(0). At the times shown, 50-J aliquots containing 0.5 pmol of G- 
proteins were removed and GTPyS binding was determined by filtra- 
tion on nitrocellulose filters. Non-specific binding was less than 
0.3%. Data shown are from one experiment carried out in duplicate 
which is representative of the three performed. 
of compound 48/80 stimulated the rate of binding of 
GTPyS to G-proteins in the presence of 1 mM of Mg2+ 
while the maximal amount of GTPyS binding remained 
unaltered. Higashijima et al. reported similar results 
with the amphiphilic tetradecapeptide mastoparan and 
demonstrated that this effect was due to the enhance- 
ment of the dissociation rate of GDP allowing a faster 
rate of association for the labeled [35S]GTPyS [l]. 
The mechanism of mastoparan, substance P and 
compound 48180 in the activation of rat peritoneal 
mast cell involves the activation of phospholipase C 
through a Bordetella pertussis toxin-sensitive G-protein 
[3,7,19]. When examined on the purified calf brain 
PTX-sensitive G-proteins, all three stimuli of mast cells 
exocytosis stimulated the GTPase activity in the pres- 
ence of 0.1 mM Mg2+ (fig.2). The presence of Mg’+ has 
been shown to be necessary for the full activation of the 
G-proteins [18] and, in fact, mastoparan seemed to 
reduce the Mg2+ concentration required for the GTPase 
stimulation. In the presence of mastop,aran, maximal 
activation could be evidenced at 100 nM of Mg2+ while 
1 mM was needed in its absence [l]. In agreement with 
these results, table I indicates that basal GTPase activi- 
ty regularly increased from 0.1 to 10 mM Mg2+, where- 
as in the presence of substance P and compound 48/80, 
the GTPase activity was already maximal at 0.1 mM. 
Also similar to the previously reported effect of 
mastoparan [I I, increasing the Mg”’ concentration 
above 1 mM slightly decreased the activity of G- 
proteins in the presence of substance P or compound 
48/80. These results indicate that substance P and com- 
pound 48/80 act similarly to mastoparan on purified G- 
proteins. 
Fig.2 Time-dependent effect of various secretagogues on the GTPase 
activity. Effects of peptides and compound 48/80 on the GTPase ac- 
tivity were determined on G-proteins reconstituted into phospholipid 
vesicles. G-proteins (1 pmol/assay) were incubated at 25°C for the 
times shown in the abscissa in buffer A that contained 0.1 mM of free 
Mg’+ (see table l), and 0.1 ,NM of [Y-~‘P]GTP either without (0) or 
with 100&M of mastoparan (m), 3OOcM of substance P (e) or 
100 rg/ml of compound 48180 (A). Activities shown are expressed as 
molar turnover numbers. 
To further validate our hypothesis, the order of 
potency of various drugs on the GTPase activation was 
compared with their ability to induce histamine release 
on mast cells. Substance P belongs to the neurokinin 
group of peptides bearing the C-terminal sequence 
-Phe-X-Leu-Met-NH2. Besides substance P, mam- 
malian neurokinins include neurokinin A and neuro- 
kinin B. These three peptides are the endogenous 
ligands of NKl, N& and NK3 receptors, which can be 
stimulated by nanomolar concentrations of the respec- 
tive peptides [20], On mast cells, the effect of substance 
P is observed from 10e6 to 10m4 M, while neurokinin A 
and neurokinin B did not significantly stimulate 
histamine release at these concentrations [Zl]. Fig.3 
reveals that both neurokinins A and B were unable to 
modify the GTPase activity of purified G-proteins at 
1 mM, whereas substance P was already active at 
0.1 mM. This observation strengthens the view that G- 
Table 1 
Effect of substance P and compound 48/80 on the GTPase activity of 
G-proteins at varying concentrations of Mg2+ 
IMg”] 
(mM) Control 
GTPase (mm-’ x 103) 
Substance P Compound 
48/80 
0 0.48 3.93 9.09 
0.1 6.89 41.17 70.01 
0.3 8.19 42.83 74.79 
1 12.63 41.31 78.71 
3 23.33 39.85 68.39 
10 40.12 38.61 71.69 
The activity of G-proteins reconstituted into phospholipid vesicles 
was assayed as described in the legend of fig.2 with varying concentra- 
tions of MgS04 and EDTA to give the calculated concentration of 
free Mg2+ indicated. Substance P and compound 48180 were tested at 
a concentration of 300 pM and 100 .&ml, respectively. Activities are 
expressed as molar turnover numbers 
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Fig.3. Effect of increasing concentrations of peptides and compound 
48/80 on the GTPase activity. The GTPase activity was measued on 
reconstituted G-proteins (1 pmol) after a 5-min incubation in the 
presence of 0.1 ,uM of [y-‘*P]GTP as described in the legend to fig.2. 
The effects of increasing concentrations of mastoparan (m), substance 
P (0) and the two neurokinins A (0) and B (0) are depicted in this 
figure. Since compound 48/80 (A) is a mixture of polymers, its con- 
centration is expressed in,ug/ml and its dose-response curve is shown 
in the inset. Activities are expressed as molar turnover numbers. 
proteins might be the target of substance P in rat perito- 
neal mast cells and in human skin mast cells, consider- 
ing the effect of peptides on this cellular type [6]. 
Substance P activates mast cells at slightly higher 
concentrations than mastoparan [3] and this difference 
can also be seen in the stimulation of G-proteins (fig.3). 
It is interesting to note that the maximal GTPase activa- 
tion by substance P (0.3 mM) was lower than the effect 
obtained by mastoparan at 0.1 mM. Compound 48’80 
is a mixture of polymers obtained from the condensa- 
tion of p-methoxyphenethylamine with formaldehyde 
and therefore, its concentration cannot be reported on 
a molar scale (fig.3, inset). Compound 48/80 activated 
mast cells from 0.01 to 0.5 pg/ml [3,7,22] and purified 
brain G-proteins from 1 to 100 ,ug/ml (fig.3). Thus, the 
secretagogue molecules were more active on intact cells 
than on their purified putative targets. One might 
assume that the shift in the active concentrations on the 
two systems is related to differences in the phospholipid 
bilayers of reconstituted vesicles or intact cell mem- 
branes. Indeed, before these cationic compounds can 
interact with G-proteins, they need to cross the plasma 
membrane, possibly through an electrolytic transfer 
process as proposed for mastoparan [11. We have found 
that neuraminidase treatment induced the desensitiza- 
tion of mast cells implying that negative charges of 
sialic acid residues facilitate the action of these 
secretagogues [3]. The nature of the G-protein itself 
could account for the higher potency at the cellular level 
since the effect of mastoparan has been shown to be 
greater on G, and Gi than on G, and Gt [ 11. In this re- 
spect, it is clear that, coupled to phospholipase C, mast 
cells possess a form of soluble PTX-sensitive G-protein 
which may not be present in the brain [7]. It thus re- 
mains possible that this G-protein is more sensitive to 
substance P or 48/80 than the brain G,/Gi. 
In summary, our results clearly extend the similarities 
of actions of substance P, compound 48/80 and 
mastoparan on mast cells to the parallel effect obtained 
on purified G-proteins. This suggests that the direct ac- 
tivation of a G-protein might be the mechanism of ac- 
tion on mast cells of all these molecules and, for sub- 
stance P, would be its physilogical pathway on mast 
cells. Although not yet completely understood, 
mastoparan was proposed to stimulate G-proteins by 
mimicking part of the intracellular loop of G-protein- 
coupled receptors [l] and it is likely that the same mech- 
anism occurs for the G-protein stimulation by sub- 
stance P and compound 48/80. 
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